# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-26-002988
**Filing Date:** 2026-5
**Character Count:** 17054
**Document Hash:** e9bb98ff5199346cb5ff526389e008aa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002988.hdr.sgml**: 20260529

**ACCESSION NUMBER**: 0001178913-26-002988

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260529

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260529

**DATE AS OF CHANGE**: 20260529

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42253
- **FILM NUMBER:** 261038975

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

?xml version='1.0' encoding='ASCII'?

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 29, 2026** 

**Silexion Therapeutics Corp**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands**<br>| **001-42253**<br>| **N/A** |
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer |
| of incorporation) |  | Identification No.) <br>|

---

---

| | |
|:---|:---|
| **12 Abba Hillel Road**<br>**Ramat-Gan, Israel**<br>| **5250606**<br>|
| (Address of principal executive offices) | (Zip Code) <br>|

---

**+972-3-756-4999**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Ordinary Shares, par value $0.135 per share<br>**  | **SLXN<br>**  | **The Nasdaq Stock Market LLC<br>**  |
| **Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share<br>**  | **SLXNW<br>**  | **The Nasdaq Stock Market LLC<br>**  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 3.03** | **Material Modification to Rights of Security Holders.** |

---

In connection with its previously-announced 1-for-10 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares (the "**Reverse Share Split**") described in Item 5.03 below, on May 29, 2026, Silexion Therapeutics Corp (the "**Company**") issued a notice (the "**Warrant Adjustment Notice")** to holders of its public warrants and private warrants to purchase the Company's ordinary shares (the "**Warrants**"). In the Warrant Adjustment Notice, the Company notified Warrant holders that the Company has made the following adjustments to its outstanding Warrants, effective after the close of trading on May 28, 2026, as reflected in the Warrants upon the open of trading on May 29, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The number of ordinary shares issuable upon the exercise of each pre-Reverse Share Split Warrant to purchase
 one ordinary share will decrease proportionately to the Reverse Share Split ratio, resulting in each such Warrant being exercisable for 1/10th of an ordinary share following the Reverse Share Split; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The exercise price of each post-Reverse Share Split Warrant to purchase one whole post-Reverse Share Split ordinary share will be
 proportionately increased ten-fold (relative to a pre-Reverse Share Split Warrant to purchase one pre-Reverse Share Split ordinary share), to $15,525.00 per post-Reverse Share Split ordinary share.

The Warrant Adjustment Notice was provided by the Company pursuant to the terms of the Warrant Agreement, dated February 19, 2021 (the "**Warrant Agreement**"), by and between Moringa Acquisition Corp, a Cayman Islands exempted company ("**Moringa**") and Continental Stock Transfer & Trust Company, as warrant agent (the "**Warrant Agent**"). Moringa's rights and obligations under the Warrant Agreement were assigned to, and assumed by, the Company pursuant to that certain Assignment, Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa, the Company and the Warrant Agent as part of the business combination transactions that were completed on August 15, 2024.

The Company will not issue fractional shares upon exercise of Warrants to purchase fractional shares following the Reverse Share Split, as any such fractional shares issuable under a Warrant will be rounded up (on the level of brokers that are DTC participants) to the nearest whole number of ordinary shares. Issuance of that rounded number of ordinary shares will be subject to payment of the full exercise price for that whole number of underlying ordinary shares.

The CUSIP number for the Warrants will remain G1281K 114 and the trading symbol for the Warrants will continue to be "SLXNW" even following the foregoing adjustments to the Warrants.

A copy of the Warrant Adjustment Notice is filed as Exhibit 4.1 hereto and is incorporated herein by reference.

------

---

| | |
|:---|:---|
| **Item 5.03** | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.** |

---

As previously reported by the Company, at the reconvened extraordinary general meeting of the Company held on May 5, 2026, the Company's shareholders approved the Reverse Share Split (as described in Item 3.03 above).

On May 28, 2026, the Company's Board of Directors, acting pursuant to that approval by the Company's shareholders, effected the Reverse Share Split following the close of trading on the Nasdaq Capital Market through the filing of a certificate with the Companies Registry of the Cayman Islands that served as an effective amendment to the Company's Amended and Restated Memorandum of Association (the "**Memorandum Amendment**"). As a result of that filing, the authorized share capital of the Company remains at $796,500, now consisting of 5,900,000 ordinary shares, and the par value of the ordinary shares has increased from $0.0135 per share to $0.135 per share. In addition, the number of issued and outstanding ordinary shares has decreased at a ratio of 1-for-10.

The Reverse Share Split became effective after the close of business on May 28, 2026, and the Company's ordinary shares will begin trading on a Reverse Share Split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol "SLXN" at the market open on May 29, 2026. After the Reverse Share Split, the trading symbol for the Company's ordinary shares will continue to be "SLXN." The new CUSIP number for the Company's ordinary shares is G1281K148.

The above description of the Memorandum Amendment and the Reverse Share Split is a summary of the material terms thereof and is qualified in its entirety by reference to the Memorandum Amendment, a copy of which is attached as Exhibit 3.1 hereto, as filed with the Companies Registry of the Cayman Islands on May 28, 2026.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

The information set forth in Items 3.03 and 5.03 is hereby incorporated by reference into this Item 8.01.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| [<u>3.1</u>](exhibit_3-1.htm) | [<u>Memorandum Amendment, dated May 28, 2026.</u>](exhibit_3-1.htm) |
| [<u>4.1</u>](exhibit_4-1.htm) | [<u>Warrant Adjustment Notice, dated May 29, 2026.</u>](exhibit_4-1.htm) |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SILEXION THERAPEUTICS CORP** | **SILEXION THERAPEUTICS CORP** |
| Date: May 29, 2026 | By: | /s/ Ilan Hadar |
|  | Name: | Ilan Hadar |
|  | Title: | Chief Executive Officer |

---

------

## Ex-99

####  

#### <br>

#### Exhibit 3.1

#### REGISTERED OFFICE CERTIFICATE
OF

#### SILEXION THERAPEUTICS CORP
Cricket Square, Hutchins Drive

P.O. Box 2681

Grand Cayman KY1-1111

Cayman Islands<br>

We, Conyers Trust Company (Cayman) Limited, Registered Office of **Silexion Therapeutics Corp** (the "**Company**") **DO HEREBY CERTIFY** that the following is a true extract of the ordinary resolution passed at the extraordinary general meeting by the shareholders of the Company dated May 5th 2026, effective 28 May 2026 and that such resolution has not been modified.

#### <br>

#### "Reverse Share Split Proposal
*RESOLVED, as an ordinary resolution, that, subject to the determination, confirmation and approval of the board of directors of the Company that this resolution is an effective means of maintaining compliance with the minimum bid price requirement for the continued listing of the ordinary shares of the Company on the Nasdaq Capital Market, the authorized share capital of the Company (after increase pursuant to the adoption of the Authorized Share Capital Increase Proposal at the Meeting) be consolidated at a ratio of 1-for-10 (subject to reduction of that ratio to the extent needed to maintain a sufficient number of publicly held shares as required under the Nasdaq listing rules) as follows:*

*from US$796,500 divided into 59,000,000 ordinary shares of a par value of US$0.0135 each,*

*to US$796,500 divided into 5,900,000 ordinary shares of a par value of US$0.135 each*

*by*

(a) the consolidation of all issued ordinary shares (as of April 7, 2026, 4,074,710 issued shares) of a par value of US$0.0135 into issued ordinary shares (based on the number of issued shares as of April 7, 2026, 407,471 issued ordinary shares) of a par value of US$0.135, and

(b) the consolidation of all unissued ordinary shares (as of April 7, 2026, as adjusted to reflect an increase due to the adoption of the Authorized Share Capital Increase Proposal at the meeting, 54,925,290 unissued shares) of a par value of US$0.0135 into unissued ordinary shares (as of April 7, 2026 and following the adoption of the Authorized Share Capital Increase Proposal at the meeting, 5,492,529 unissued shares) of a par value of US$0.135."

<u>/s/ Melanie Whittaker</u>

Melanie Whittaker

for and on behalf of

Conyers Trust Company (Cayman) Limited

Registered Office

Dated this 28th day of May 2026

------

## Ex-99

#### <br>

#### Exhibit 4.1
**SILEXION THERAPEUTICS CORP**

May 29, 2026

#### Notice to Warrant Holders
Dear Warrant Holder:

Reference is made to that certain Warrant Agreement (the "**Warrant Agreement**"), dated as of February 19, 2021, by and between Moringa Acquisition Corp, a Cayman Islands exempted company ("**Moringa**") and Continental Stock Transfer & Trust Company, as warrant agent (the "**Warrant Agent**"), under which the rights and obligations of Moringa were assigned to, and assumed by, Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (the "**Company**") pursuant to that certain Assignment, Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa, the Company and the Warrant Agent. All capitalized terms not separately defined in this Notice shall have the same meanings as defined in the Warrant Agreement.

We are writing to inform you, as a registered holder of one or more Warrants, that the Company has effected a reverse share split of the issued and outstanding ordinary shares of the Company, par value $0.0135 per share (the "**Reverse Share Split**"). The Board of Directors and shareholders of the Company have approved the Reverse Share Split at a ratio of one (1) post-Reverse Share Split share for every ten (10) pre-Reverse Share Split shares and the Reverse Share Split became effective following the close of trading on the Nasdaq Capital Market ("**Nasdaq**") on May 28, 2026 (the "**Effective Date**"). The Company's ordinary shares will begin trading on Nasdaq on a post-Reverse Share Split basis under the Company's existing trade symbol "SLXN", at the market open on May 29, 2026.

The Reverse Share Split has also resulted in a proportional decrease in the number of authorized ordinary shares and a proportional increase in the par value of the ordinary shares in accordance with the Reverse Share Split ratio. Following the effectiveness of the Reverse Share Split, the Company is now authorized to issue 5,900,000 ordinary shares, par value US$0.135 per ordinary share.

Prior to the Effective Date, each whole Warrant was exercisable for one (1) ordinary share of the Company at a Warrant Price of $1,552.50 per share. Pursuant to Sections 4.2 and 4.3 of the Warrant Agreement, as of the Effective Date, each then-outstanding whole Warrant will be adjusted such that (subject to any future adjustment pursuant to the Warrant Agreement's terms):

• the number of ordinary shares issuable upon exercise of each whole pre- Reverse Share Split Warrant shall be decreased in proportion to the decrease of the number of issued and outstanding ordinary shares of the Company following the Reverse Share Split, resulting in such Warrant being exercisable for one-tenth (1/10) of an ordinary share; and

• &nbsp;&nbsp;&nbsp;&nbsp; the Warrant Price (for the exercise of each post- Reverse Share Split Warrant for one whole underlying ordinary share) shall be adjusted by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be one (1) (*i.e.*, the number of ordinary shares purchasable upon the exercise of one whole Warrant immediately prior to such adjustment), and (y) the denominator of which shall be one-tenth (1/10) (*i.e.*, the number of ordinary shares so purchasable immediately thereafter), resulting in an adjusted Warrant Price of $15,525.00 per post-Reverse Share Split ordinary share.

In accordance with Section 4.6 of the Warrant Agreement, the Company will not issue fractional shares upon exercise of Warrants following the Reverse Share Split. If, by reason of the adjustments to the Warrants made in relation to the Reverse Share Split, the holder of any Warrant who is a participant in the Depository Trust and Clearing Corporation system would be entitled, upon the exercise of such Warrant, to receive a fractional interest in an ordinary share, the Company will, upon such exercise and payment of the full exercise price for the rounded number of shares, round up to the nearest whole number the number of ordinary shares to be issued to the Warrant holder.

The Reverse Share Split was approved by the shareholders of the Company at an extraordinary general meeting initially held on April 28, 2026, which was adjourned and reconvened on May 5, 2026.

If you should have any questions, please do not hesitate to contact either of the below contacts via email at:

Silexion Therapeutics Corp<br> Ms. Mirit Horenshtein Hadar, CFO<br> <u>mirit@silexion.com</u>

ARX \| Capital Markets Advisors<br> North American Equities Desk<br> <u>silexion@arxadvisory.com</u>

 

<br> ------

<u> </u>